Perceptive Advisors

Perceptive Advisors

Signal active

Investment Firm

Overview

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.

Highlights

Founded

1999

Industry

Financial Services

Employees

11-50

Investment

279

Lead Investment

95

Exits

144

Stages

Early Stage Venture, Late Stage Venture, Private Equity, Seed

Investor Type

Hedge Fund

Location

New York, New York, United States, North America

Contact Information

Social

Profile Resume

Perceptive Advisors, established in 1999 and headquartered in New York, New York, United States, North America., specializes in Early Stage Venture, Late Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Pharmaceutical, Medical, Oncology, Financial Services, Venture Capital, Finance, Biopharma, Therapeutics. The organization boasts a portfolio of 277 investments, with an average round size of $109.7M and 144 successful exits. Their recent investments include EUSA Pharma, Iroquois Capital, Highbridge Capital Management, Sevion Therapeutics, Alpha Capital. The highest investment round they participated in was $3108.3B. Among their most notable exits are EUSA Pharma and Iroquois Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.

Employees

imagePlace Joseph Edelman

Joseph Edelman

CEO & Founder

imagePlace Adam Stone

Adam Stone

Chief Investment Officer

imagePlace Orly Mishan

Orly Mishan

Managing Director, Perceptive Discovery

imagePlace Ellen Hukkelhoven

Ellen Hukkelhoven

Managing Director

Investment portfolio

Perceptive Advisors has made 279 investments. Their most recent investment was on Aug 12, 2024, when scPharmaceuticals raised $125.0M.

Perceptive Advisors has made 76 diversity investments. Their most recent diversity investment was on Jun 18, 2024, when Talkiatry raised $130.0M.

investments

279

Diversity investments

76

Lead investments

95

Number of exits

144

Investments

279

Annouced DateOrganization NameIndustryMoney Raised
Jun 18, 2024--190.0M
Jun 18, 2024
InSightec InSightec
Biotechnology150.0M
Jul 26, 2024
Confo Therapeutics Confo Therapeutics
Biotechnology65.1M
Aug 12, 2024
scPharmaceuticals scPharmaceuticals
Biotechnology125.0M

Exits

144

Funding Timeline

Funding rounds

279

Investors

0

Funds

4

Funding Rounds

279

Perceptive Advisors has raised 279 rounds. Their latest funding was raised on Aug 12, 2024 from a Post-IPO Debt - scPharmaceuticals round.

Annouced DateTransaction NameNumber of InvestorsMoney RaisedLead Investor
Jun 18, 2024
Series B - Marea Therapeutics Series B - Marea Therapeutics
-190.0M-
Jun 18, 2024
Private Equity Round - InSightec Private Equity Round - InSightec
-150.0M-
Jul 26, 2024
Series B - Confo Therapeutics Series B - Confo Therapeutics
-65.1M-
Aug 12, 2024
Post-IPO Debt - scPharmaceuticals Post-IPO Debt - scPharmaceuticals
-125.0M-

Investors

0

There is no funding round available on this profile

Fund raised

2

Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.

Annouced DateFund NameMoney Raised
May 10, 2013
fund image OTPPLESS
1.0M
May 11, 2013
fund image OTPPLESS
1.0M

Invest in industries

Recent Activity

There is no recent news or activity for this profile.